Company: ANIX
Filing Date: 2025-09-10
Form Type: 10-Q
Source: 0001493152-25-013000
Chunk: 30

Company: Anixa Biosciences Inc
Filing Date: 2025-09-10
Form: 10-Q
Item: Part I, Item 1
Chunk 30
---
 concerning
future events and results. We generally use the words “believes,” “expects,” “intends,” “plans,”
“anticipates,” “likely,” “will” and similar expressions to identify forward-looking statements. Such
forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which
are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different
from any future results, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties
and factors include, but are not limited to, those factors set forth in our Annual Report on Form 10-K for the fiscal year ended October
31, 2024. Except as required by applicable law, including the securities laws of the United States, we undertake no obligation to publicly
update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned
not to unduly rely on such forward-looking statements when evaluating the information presented in this Report.

GENERAL

We
discuss the description of our business in the Notes to our Condensed Consolidated Financial Statements.

RESULTS
OF OPERATIONS

Three
months ended July 31, 2025 compared with three months ended July 31, 2024

Revenue

We
had no revenue during the three-month periods ended July 31, 2025 and 2024.

We
have not generated any revenue to date from our therapeutics or vaccine programs. In addition, while we pursue our therapeutics and vaccine
programs, we may also make investments in and form new companies to develop additional emerging technologies. We do not expect to begin
generating revenue with respect to any of our current therapy or vaccine programs in the near term. We hope to achieve a profitable outcome
by eventually licensing our technologies to large pharmaceutical companies that have the resources and infrastructure in place to manufacture,
market and sell our technologies as therapeutics or vaccines. The eventual licensing of any of our technologies may take several years,
if it is to occur at all, and may depend on positive results from human clinical trials.

Research
and Development Expenses

During
the three months ended July 31, 2025, research and development expenses related to the development of our cancer vaccines and CAR-T therapeutics
consisted of approximately $615,000 and $440,000, respectively. During the three months ended July 31, 2024 research and development